Clinical trial
Antiviral & Antifibrotic Liver Therapy in HCV + Drinkers and Non-Drinkers
NCT00211848 · Icahn School of Medicine at Mount Sinai, Other · Completed
Key facts
| NCT number | NCT00211848 |
|---|---|
| Title | Antiviral & Antifibrotic Liver Therapy in HCV + Drinkers and Non-Drinkers |
| Official title | Antiviral & Antifibrotic Liver Therapy in HCV + Drinkers and Non-Drinkers |
| Lead sponsor | Icahn School of Medicine at Mount Sinai, Other |
| Collaborators | National Institute on Alcohol Abuse and Alcoholism (NIAAA) NIH Hoffmann-La Roche Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Hepatitis C |
| Intervention type | Drug |
| Interventions | Polyenylphosphatidylcholine (PPC), Pegylated Interferon, Ribavirin |
| Enrollment | 207 |
| Start date | Jun 1, 2000 |
| Primary completion | Dec 1, 2005 |
| Completion | Dec 1, 2005 |
| First posted | Sep 21, 2005 |
| Last update posted | Jan 27, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: